Background-Abdominal aortic aneurysms are a major cause of death. Prediction of aneurysm expansion and rupture is challenging and currently relies on the simple measure of aneurysm diameter. Using MRI, we aimed to assess whether areas of cellular inflammation correlated with the rate of abdominal aortic aneurysm expansion. Methods and Results-Stable patients (nϭ29; 27 male; age, 70Ϯ5 years) with asymptomatic abdominal aortic aneurysms (4.0 to 6.6 cm) were recruited from a surveillance program and imaged using a 3-T MRI scanner before and 24 to 36 hours after administration of ultrasmall superparamagnetic particles of iron oxide (USPIO). The change in T2* value on T2*-weighted imaging was used to detect accumulation of USPIO within the abdominal aortic aneurysm. Histological examination of aneurysm tissue confirmed colocalization and uptake of USPIO in areas with macrophage infiltration. Patients with distinct mural uptake of USPIO had a 3-fold higher growth rate (nϭ11, 0.66 cm/y; Pϭ0.020) than those with no (nϭ6, 0.22 cm/y) or nonspecific USPIO uptake (nϭ8, 0.24 cm/y) despite having similar aneurysm diameters (5.4Ϯ0.6, 5.1Ϯ0.5, and 5.0Ϯ0.5 cm, respectively; PϾ0.05). In 1 patient with an inflammatory aneurysm, there was a strong and widespread uptake of USPIO extending beyond the aortic wall.
5% in men over the age of 65 years, and acute rupture is associated with a mortality rate of 65% to 85%. AAAs are responsible for 2% to 3% of deaths in men age Ն65 years and account for Ͼ15 000 deaths in the United States. [1] [2] [3] Open surgical or endovascular intervention to prevent rupture is considered when the perceived risk of rupture outweighs the risk of procedural complications with a diameter threshold of 5.5 cm being considered the appropriate time to intervene. 4 -6 However, up to one-fifth of ruptured AAA are Ͻ5.5 cm in diameter, 7 and many patients present with AAA diameters considerably Ͼ5.5 cm without prior symptoms or rupture. 8 Apart from the simple measurement of aneurysm diameter, there are currently no methods of predicting which patients with AAA are at risk of further aneurysm growth and rupture. We therefore need better methods to guide preventative intervention in these patients.
Clinical Perspective on p 281
Aortic aneurysms arise when the aortic wall develops excessive medial neovascularization, infiltration of macrophages and lymphocytes, and irreversible proteolytic degradation and remodeling of the extracellular matrix. These pathological processes do not affect the aorta uniformly but are focal in nature with mural neovascularization, inflammation, and matrix metalloproteinase (MMP) activity occurring at sites of low tensile strength 9 and AAA rupture. 10 -12 These areas of increased biological activity within the aortic aneu-rysm wall are therefore putative targets for novel imaging techniques.
MRI is emerging as a useful investigative tool for cardiovascular disease that can distinguish the different atherosclerotic plaque components, such as the lipid-rich core and areas of calcification. 13 Standard gadolinium-based MRI identifies areas of thrombus formation and fibrosis in abdominal aortic aneurysms. 14 Recently, a novel class of MRI contrast agents containing superparamagnetic particles of iron oxide (SPIO) has been developed that provides additional biological and functional information through the detection of cellular inflammation within tissues. Ultrasmall SPIO (USPIO), with particle sizes in the range 10 to 30 nm, escape immediate recognition by the reticulo-endothelial system and persist for longer in the bloodstream allowing them to be used to assess the accumulation of macrophages within vascular and lymphatic tissues. [15] [16] [17] [18] [19] Current preparations are biodegradable and safe for clinical administration. 20 -22 USPIO accumulate in the aortas of hypercholesterolemic rabbits 23 and in murine models of AAAs. 24 In humans, USPIO accumulate in ruptured or rupture-prone carotid plaques rather than stable plaques, 17, 18 and treatment with atorvastatin reduces both inflammation and USPIO uptake in carotid plaques. 19 However, the use of USPIO has not been explored in patients with AAAs. The aims of this study were to determine whether USPIO uptake can be used to detect areas of cellular inflammation within the wall of the AAA and to determine whether this correlates with aneurysm growth rates.
Methods

Subjects
Patients were recruited from the outpatient aneurysm surveillance program at the Royal Infirmary of Edinburgh between August 2009 and December 2009. Patients had an AAA with a diameter Ͼ4.0 cm on ultrasound examination of the aorta. Patients who were under the age of 40 years or pregnant and those who had active systemic inflammatory or malignant disease, renal dysfunction (estimated glomerular filtration rate Ͻ25 mL/min), hepatic cirrhosis (Child Pugh score B or C), or a contraindication to MRI scanning were excluded from the study. The research ethics committee and the Medicines and Healthcare Products Regulatory Agency approved the study, which was conducted in accordance with the Declaration of Helsinki. All participants gave written informed consent.
Demographic and clinical data, including medical history and medications, were obtained through patient interview and source hospital records. Patients were being monitored in the aneurysm surveillance program involving serial ultrasound-based measurements of the maximum anteroposterior diameter of the AAA, usually at 6-month intervals. Scans were undertaken by accredited clinical vascular scientists with interobserver coefficient of variation of aortic diameter measurements of 3.5% in our laboratory. 25 Because of the stacatto growth pattern of AAA and need for a contemporary measurement, 26 the annual growth rate was determined from 2 ultrasound scans performed 6 months apart, with one conducted before and the other after the MRI examination.
Contrast Agent Administration
The preparation containing USPIO (Sinerem, Guerbet, France) consists of iron oxide nanoparticles stabilized with dextran and sodium citrate. Supplied as a dry powder, it was first reconstituted in 10 mL of 0.9% saline and then the weight-adjusted dose of 2.6 mg/kg was diluted further in 100 mL of 0.9% saline. The USPIO was then administered through a filter as a slow infusion over 30 minutes through a peripheral 20G intravenous cannula.
Magnetic Resonance Imaging
Participants underwent MRI in a whole-body, 3-T Siemens Magnetom Verio scanner (Siemens, Erlangen, Germany) before and 24 to 36 hours 27 after administration of the contrast agent. Routine clinical coronal and sagittal breath-held T2-weighted multislice HASTE localizer sequences were used to identify the position and extent of the aneurysm, after which a respiratory-gated, ECG-triggered T2weighted (T2W) turbo spin-echo sequence was used to acquire detailed anatomic data (TR/TE 2R-R intervals/72 ms; flip angle, 180°; matrix, 192ϫ256; field of view, 400ϫ400 mm; slice width, 5 mm). A multi-echo, gradient-echo T2*W sequence (TE, 4.9, 7.7, 10.5, 13.3 ms; TR, 133 ms; flip angle, 15°; matrix 192ϫ256; field of view 400ϫ400 mm; slice width 5 mm) was used to acquire axial images of the entire aneurysm with slice positions corresponding to those of the T2W images. The echo times for the T2*W sequences were selected such that fat and water were in-phase for each echo to minimize phase shift artifact and errors in T2* measurements. The field of view used for both sequences was typically 400ϫ400 mm but was adjusted for larger subjects to minimize phase-wrap artifacts. T2W images give excellent discrimination of the boundaries between the flow lumen, thrombus, wall, and surrounding tissues. T2*W sequences have less distinct soft tissue contrast but are exquisitely sensitive to the effects of USPIO accumulation. At the postcontrast scan, slice positions were selected to match those of the precontrast scan as closely as possible by reference to the vertebral bodies.
In a subset of 19 patients, T1W images were acquired before and 5 minutes after the bolus administration of 0.2 mg/kg of gadolinium (Dataram, Guerbet Pharmaceuticals, France), using a turbo spin-echo acquisition (TR/TE 1 R-R interval/28 ms; flip angle, 180°; matrix, 192ϫ256; field of view, 400ϫ400 mm; slice width, 5 mm). Gadolinium-enhanced sequences were performed after the baseline T2W and T2*W sequences were acquired, 2 hours before USPIO administration and approximately 24 hours before the post-USPIO MRI scan. Because gadolinium has a plasma half-life in the region of 2 hours and, unlike USPIO, is not readily taken up into the intracellular compartment, USPIO enhancement is unlikely to have been affected by preadministration of gadolinium.
Image Analysis
So that the soft tissue discrimination of the T2W images could be used to complement the iron sensitivity of the T2*W images, and to allow direct comparison of the precontrast and postcontrast data, all the images were registered to the precontrast T2W image using a semiautomatic rigid 3D voxel registration protocol (Analyze, Mayo Clinic). Bowel and abdominal wall motion were found to compromise registration of the aorta itself and this was minimized by excluding these structures from the volume for registration as far as possible. A region of interest (ROI) encompassing the aortic wall and thrombus but excluding the flow lumen was drawn on each slice of the precontrast T2W image. The 4 echoes in the multi-echo T2*W sequence were combined to generate a T2* map, in which the data represented the T2* value [S(t)ϭS(0)expϪ(t/Ts*)] for each voxel. The T2* value is the decay constant for the exponential decay of signal intensity with time. In the presence of USPIO, the signal decays more rapidly due to local field inhomogeneities and the T2* value is reduced. A 3ϫ3 voxel gaussian filter was applied to the individual echoes to reduce noise, and experimentally determined thresholds for the coefficient of determination (r 2 Ͼ0.4) and sum of squared deviations due to error (SSE Ͻ0.2) were used to exclude data that did not have an acceptable straight-line fit when ln signal intensity (SI) was plotted against echo time.
The previously delineated ROI was applied to the T2* maps that had been registered to the precontrast T2W scan. The percent change in T2* value (%⌬T2*) after the administration of USPIO was calculated on a voxel-by-voxel basis and displayed on a color scale (%⌬T2*ϭ(T2* value scan 1ϪT2* value scan 2)/(T2* value scan 1)ϫ100). From the 95th percentile of the %⌬T2* value observed in a group of patients not receiving USPIO, we established a threshold of significance for %⌬T2* of 59%, above which an observed change in T2* value can be attributed to USPIO uptake. All voxels with values for %⌬T2* below this threshold appear blue on the color map, whereas voxels above this threshold appear on a yellow-red color scale. This facilitates data interpretation and minimizes observer bias.
To assess the gadolinium enhancement on T1W images, the precontrast and postcontrast images were registered to the precontrast T2W image. The previously delineated ROI was applied to the T1 images. The percent change in SI was calculated (%⌬ SI) on a voxel-by-voxel basis and displayed on a color scale (%⌬ SIϭ(SI scan 2ϪSI scan 1)/(SI scan 1)ϫ100). By convention, an increase in SI of Ͼ50% of the baseline value was taken to be significant.
Classification of Aneurysms
Cellular inflammation is an important pathological process in the development of AAA, with the associated proteolytic degradation of the aortic wall representing the key step leading to AAA expansion and rupture. We were interested to see whether aneurysm expansion rate is increased in aneurysms with USPIO uptake in (1) the aortic wall or (2) the associated thrombus. Therefore, 2 independent observers, blinded to the patient demographics, and aneurysm diameter, and growth rate, reviewed the color map images and classified them into 3 clear predefined groups according to their appearance:
Group 1 had no mural or thrombus USPIO uptake, except for isolated periluminal T2* enhancement occurring immediately adjacent to, and in continuity with, the lumen.
Group 2 had diffuse USPIO uptake that was distinct from the periluminal thrombus and the aortic wall.
Group 3 had focal areas (with at least 10 contiguous voxels) of USPIO uptake within the aortic wall of the aneurysm distinct from periluminal area and thrombus.
Differences in classification were resolved by consensus.
Histology
For patients undergoing open surgical repair within 48 hours of USPIO administration, samples of aortic wall were obtained from the arteriotomy site on the anterior aspect of the aneurysm sac. Samples were fixed in formalin, embedded in paraffin, sectioned, and stained to look at the architecture (hematoxylin and eosin and elastin-van Gieson) and USPIO accumulation (Prussian blue). The distribution of macrophages was assessed by immunohistochemical staining for macrophages (mouse, anti-human CD68 monoclonal antibody; DAKO).
Statistical Analysis
The data were normally distributed. Continuous data were compared with 1-way ANOVA with Tukey post test comparison (Minitab), and categorical data were analyzed using the 2 test with cross-tabulation (SPSS). Statistical significance was taken as 2-sided PϽ0.05.
Results
Patients
Twenty-nine patients (27 male) were recruited into the trial, with a mean age of 70Ϯ5 years and mean AAA diameter of 5.2 cm (range, 4.0 to 6.6 cm). All aneurysms were fusiform and confined to the abdominal aorta. One patient had an inflammatory aneurysm with ureteric obstruction and a raised erythrocyte sedimentation rate of 100 mm/h (reference range, 1 to 10 mm/h). The remaining patients were asymptomatic. As anticipated, patients had a range of cardiovascular risk factors and comorbidities (Table) . During the study period, 4 patients underwent open surgical repair of their AAA (2 in group 1 and 2 in group 3), 2 patients were treated by endovascular aneurysm repair (1 in group 2 and 1 in group 3), and 1 patient in group 3 died of a ruptured aneurysm, having been assessed and considered unfit for operative intervention. It was not possible to calculate a growth rate for 4 patients (1 in group 1, 1 in group 2, and 2 in group 3) who had only a single diameter measurement, either because they proceeded straight to surgery or had only recently presented to the surveillance program.
USPIO Administration
The administration of USPIO was well tolerated, with no significant adverse events. There was a relatively even distribution of patients within the three categories of USPIO uptake (Table) . Patients in the 3 groups were similar in terms of age, sex, use of medications, initial aneurysm diameter, and all comorbidities except hypertension (Pϭ0.024). In patients undergoing open surgical AAA repair, histology confirmed the accumulation of USPIO that colocated with immunohistochemical staining for CD68-positive macrophages (Figure 1 ).
MRI With USPIO
Patients had between 10 and 20 slices to cover the entire aneurysm with a total of 351 slices for analysis. Registration within the main body of the aneurysm was excellent for all scans although 9.7Ϯ1.39% of the data were discarded due to poor straight-line fit when ln SI was plotted against echo time. Classification of AAA according to USPIO uptake (Figure 2 ) was consistent and reproducible with excellent interobserver agreement and a statistic of 0.89. There appeared to be no differences in USPIO uptake whether or not patients had received preadministration of gadolinium. The effect of USPIO accumulation is to accelerate dephasing of transverse magnetization, resulting in rapid loss of signal with increasing echo time and hence a reduction in the decay constant, the T2* value. The magnitude of the change in T2* value was encoded for each voxel, with a large reduction in T2* value reflecting a greater accumulation of USPIO. We have previously defined a threshold (59%) above which the change in T2* value can be attributed to USPIO accumulation rather than variability of the measurement. In all patients, there was nonspecific USPIO uptake in the periluminal region consistent with transition of the particles from the blood pool ( Figure 2 ). Interestingly the same region of the thrombus enhanced rapidly on T1W MRI with gadolinium ( Figure 3 ). In group 3, in addition to the presence of focal areas of USPIO uptake (at least 10 contiguous voxels), there was a higher proportion of USPIOpositive voxels in the aortic wall compared with the other 2 groups (PϽ0.0001), supporting the correct classification of patients into the 3 groups ( Figure 4A ).
Patients with distinct focal areas of increased USPIO uptake in the wall of the aneurysm (group 3) had aneurysm growth rates that were 3-fold higher than patients without (group 1) or with nonspecific (group 2) uptake of USPIO 
Figure 2. Color maps (A through C)
showing representative abdominal aortic aneurysm (AAA) slices from patients in each of the 3 groups alongside the corresponding T2W anatomic images (D through F). The color scale represents the magnitude of the change in T2* value, with blue indicating minimal change and red indicating a large change in T2* value. We have previously defined the threshold above which changes in T2* value can be attributed to ultrasmall superparamagnetic particles of iron oxide particles (USPIO) accumulation. Only changes in T2* value above the threshold are presented on the graduated (yellow-red) color scale; data below the threshold appear blue. A distinctive pattern is seen for each patient group: A, Group 1 shows a large change in T2* value only in the periluminal area; B, group 2, diffuse patchy changes in T2* throughout the intraluminal thrombus but no distinct focal area of USPIO uptake affecting the aortic wall; and C, group 3, discrete focal area of USPIO uptake involving the wall of the AAA that is distinct from the periluminal region. This patient subsequently died suddenly from presumed ruptured AAA.
(Pϭ0.020; Figure 4B ). Interestingly, there was no difference in baseline aneurysm diameter across the three groups ( Figure  4B ). The percentage of USPIO positive voxels in the aortic wall correlated with the AAA growth rate (rϭ0.46; Pϭ0.028).
One patient in group 3 had an inflammatory aneurysm; a specific subtype of AAA characterized by systemic inflammation, a thickened, fibrosed aortic wall, and fibrosis and inflammation extending beyond the aorta into surrounding tissues. This produced a unique change in T2* pattern with intense USPIO uptake extending beyond the wall of the AAA ( Figure 5 ).
Discussion
We have shown for the first time that uptake of USPIO in AAAs identifies cellular inflammation and appears to distinguish those patients with more rapidly progressive abdominal aortic aneurysm expansion. This technique holds major promise as a new method of risk-stratifying patients with AAAs that extends beyond the simple anatomic measure of aneurysm diameter.
We used a smart contrast agent that consists of 20-nm dextran-coated iron oxide nanoparticles. After intravenous administration, these USPIO circulate within the blood pool with a long half-life and are engulfed by macrophages. They accumulate at sites of cellular inflammation at sufficient concentrations to cause signal changes on MRI. As a result of their superparamagnetic properties, they induce local field inhomogeneities leading to rapid dephasing of the transverse magnetization of spinning protons and thus loss of coherent signal. Although these agents exhibit T1 relaxivity, the predominant extravascular effect of USPIO at 3T is to cause a dropout of signal on T2W and especially T2*W images. 28 Because of the mixed T1 and T2/T2* effects of USPIO, we chose to measure their effect on the rate of exponential signal decay by calculating the decay constant, T2* value, from the signal intensities at 4 echo times rather than relying on the signal intensity at a single echo time. This proved to be a highly sensitive technique, and variations in the change of T2* value identified areas of cellular inflammation that were confirmed on subsequent histological examination of aneurysm tissue obtained at the time of open surgery.
Within the study population, we observed distinct patterns of spatial variation in the change of T2* value and were able to divide patients into 3 groups on this basis. Patients in group 1 had a high change in T2* value only in the periluminal aspect of the aneurysm, this "halo effect" being a constant finding in all study patients. Intraluminal thrombus is a consistent feature of AAA and usually has a laminar appearance with the mural component having been deposited first and subsequent growth of the thrombus occurring by further deposition of fibrin, platelets, and red blood cells on the inner luminal aspect. 29 The universal finding of a large change in T2* value in the periluminal region of the aneurysm is therefore likely to reflect trapping of USPIO in fresh potentially gelatinous thrombus that is typically friable and highly cellular because of its close proximity to flowing blood. 30 It was interesting to observe that this region also enhanced rapidly with gadolinium, consistent with a less selective and more generalized uptake of contrast agents in this region. A previous study using the larger SPIO particles (80 to 150 nm) demonstrated their accumulation in the luminal layer of aortic thrombus, resulting in an MRI signal that correlated with histological evidence of leukocyte infiltration (CD68 and CD66b) and levels of matrix metalloproteinases. 31 As acknowledged by the authors, these large SPIO particles are not well suited to vascular tissue imaging because of their short plasma half-life that limits their sensitivity for detecting vessel wall inflammation.
The second group of patients had a heterogeneous pattern of change in T2* signal within the thrombus but no uptake in the aortic wall. The role of the thrombus in aneurysm expansion and rupture is uncertain. 30, 32, 33 Some macrophages are present deep within the thrombus, but, alternatively, this signal pattern may reflect USPIO within the canaliculi that traverse the thrombus, conducting fluid, small molecules and, to a certain extent, cells from the lumen toward the aortic wall. 30 This pattern of USPIO uptake and inflammation within the thrombus is of uncertain significance but interestingly did not appear to be associated with accelerated aneurysm growth.
In the third group of patients, we found 1 or more distinct focal areas of inflammation involving the wall itself and spatially distinct from the periluminal halo. This finding was associated with an increased growth rate compared to patients without mural USPIO uptake. This high growth rate (0.66 cm/y) is clinically significant because the average aneurysm growth in screened populations is 0.26 cm/y, and growth rates Ͼ0.2 cm/y are associated with increased AAA-related events. 34 -36 We are unable to exclude the possibility that differences in the incidence of hypertension among patients in the 3 groups influenced AAA growth rate; however, this seems unlikely because the groups with the highest (group 2) and lowest (group 1) incidence of hypertension had similarly low growth rates. In patients with ruptured AAA, histology of the aneurysm wall has shown areas of increased biological activity and these correlate with a reduction in wall tensile strength. 9 -12 It would be interesting to determine whether, in patients with AAA and abdominal pain of uncertain etiology, USPIO imaging could distinguish between those with impending rupture and those with non-AAA-related abdominal pain. Finally, whether this pattern of USPIO uptake in AAA may prove to be a marker for future AAA-related events is unclear and requires a large, prospective study.
Existing techniques for surveillance of AAA and estimation of risk of rupture rely solely on diameter measurements, but clinical data from aneurysm screening and surveillance programs suggest that there is considerable scope to improve on this. Of those aneurysms detected by screening that are Ͻ5.5 cm in diameter, 1 in 14 will rupture over the following 3 years 34 and together account for up to one-fifth of all ruptured AAA. 7 However, simply reducing the diameter threshold for intervention would not improve mortality. 4, 6 Furthermore, small aneurysms exhibit a bimodal distribution for growth with half remaining small and only half continuing to grow. 34 Having been shown to reduce AAA-related mortality by 53%, aneurysm screening is being introduced in many countries across the world. 1, 37 However, screening considerably increases the number of patients under longterm surveillance, and only around 30% of these patients will require future intervention. 1, 34 Taken together, these observations support a need for a more sophisticated and individualized method of predicting clinical events in patients with AAA so that screening, surveillance, and intervention can be targeted at high-risk patients, reducing the overall economic cost and decreasing morbidity and mortality. We believe USPIO imaging represents a logical and important new approach that has the potential to address these major unmet clinical needs.
In conclusion, we have demonstrated that assessment of USPIO uptake with MRI can be used to detect focal hotspots of inflammation in asymptomatic AAA and that mural USPIO uptake is associated with more rapid expansion of AAA. A large prospective clinical trial with a longer duration of follow-up would be required to confirm the findings of the present study and assess the role of MRI and USPIO in the prediction of AAA-related clinical events. This would also enable a more sophisticated MRI-based assessment of growth and its relationship to areas of USPIO uptake. If successful, this technique has a number of potential highly relevant clinical applications that include informing selection of patients for intervention to prevent rupture, rationalization of AAA screening resources to target high-risk patients, and application as a biomarker to investigate the utility of novel therapeutic interventions for AAA.
